Compare URBN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | BLCO |
|---|---|---|
| Founded | 1970 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.0B |
| IPO Year | 1995 | 2022 |
| Metric | URBN | BLCO |
|---|---|---|
| Price | $65.88 | $17.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $86.91 | $18.55 |
| AVG Volume (30 Days) | ★ 1.3M | 437.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.67 | N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $5,550,666,000.00 | $5,101,000,000.00 |
| Revenue This Year | $10.29 | $7.45 |
| Revenue Next Year | $5.49 | $5.49 |
| P/E Ratio | $16.46 | ★ N/A |
| Revenue Growth | ★ 7.71 | 6.47 |
| 52 Week Low | $41.89 | $10.45 |
| 52 Week High | $84.35 | $18.92 |
| Indicator | URBN | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 56.00 |
| Support Level | $59.54 | $16.35 |
| Resistance Level | $74.09 | N/A |
| Average True Range (ATR) | 3.13 | 0.64 |
| MACD | -0.21 | 0.07 |
| Stochastic Oscillator | 36.65 | 63.79 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the United States, which accounts for about 87% of sales, and other regions. Its retail nameplates are Urban Outfitters (23% of fiscal 2025 sales), Free People/Movement (26%), and Anthropologie (44%). Retail accounted for 88% of fiscal 2025 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (7% of sales). Urban Outfitters primarily markets to young adults and offers products in categories such as apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.